Adding Keytruda (pembrolizumab) to standard first-line therapy with Paraplatin (carboplatin) and Alimta (pemetrexed) is a promising approach for patients with inoperable or metastatic nonsquamous non-small cell lung cancer (NSCLC), according to ... Read more